NCT01190215View on ClinicalTrials.gov

Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM

PHASE4CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

October 4, 2010

Primary Completion Date

July 7, 2011

Study Completion Date

July 7, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

FluarixTM

One Intramuscular injection

BIOLOGICAL

HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)

Two Intramuscular injections

Trial Locations (1)

33100

GSK Investigational Site, Tampere

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01190215 - Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM | Biotech Hunter | Biotech Hunter